AstraZeneca Begins Trading on the New York Stock Exchange
AstraZeneca announced that its ordinary shares have begun trading directly on the New York Stock Exchange (NYSE) under a harmonised global listing structure, aligning its U.S. listing with its London and Stockholm listings and enabling broader participation by U.S. investors. The move replaces the previous American Depositary Receipt (ADR) listing on Nasdaq and is part of AstraZeneca’s strategy to expand global investor access while maintaining its primary listings in London and Stockholm. 
AstraZeneca Begins Trading on the New York Stock Exchange